JAGUAR HEALTH, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
JAGUAR HEALTH, INC. (JAGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-19
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.00.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.00.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $0.00.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $0.00.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $30.33.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $22.04, a 94.19% decline from fiscal 2021.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $379.66, a 31538.33% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-19 | |||||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-20 | |||||||
| 2025-12-31 | $47.72 10-Q · filed 2026-08-19 | $1.36 10-K · filed 2026-04-07 | ||||||
| 2025-09-30 | $4.39 10-Q · filed 2025-11-14 | |||||||
| 2025-06-30 | $4.39 10-Q · filed 2025-08-14 | |||||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | |||||||
| 2024-12-31 | $30.33 10-K · filed 2026-04-07 | |||||||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | |||||||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |||||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | |||||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | |||||||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | |||||||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | |||||||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | |||||||
| 2022-12-31 | $22.04 10-K · filed 2024-04-01 | |||||||
| 2022-09-30 | $0.29 10-Q · filed 2022-11-14 | |||||||
| 2022-06-30 | $0.29 10-Q · filed 2022-08-22 | |||||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | |||||||
| 2021-12-31 | $379.66 10-K · filed 2023-03-24 | $5.06 10-K · filed 2022-03-11 | ||||||
| 2021-09-30 | $5.25 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | $5.06 10-Q · filed 2022-08-22 | $1.75 10-Q · filed 2021-08-13 | ||||||
| 2021-03-31 | $5.28 10-Q · filed 2022-05-10 | $1.76 10-Q · filed 2021-05-17 | ||||||
| 2020-12-31 | $1.20 10-K · filed 2022-03-11 | $0.40 10-K · filed 2021-03-31 | ||||||
| 2020-09-30 | $1.18 10-Q · filed 2021-11-17 | $0.39 10-Q · filed 2020-11-16 | ||||||
| 2020-06-30 | $0.41 10-Q · filed 2021-08-13 | |||||||
| 2020-03-31 | $0.41 10-Q · filed 2021-05-17 | |||||||
| 2019-12-31 | $1.54 10-K · filed 2021-03-31 | |||||||
| 2019-09-30 | $1.57 10-Q · filed 2020-11-16 | |||||||
| 2019-06-30 | $17.05 10-Q · filed 2020-08-13 | |||||||
| 2019-03-31 | $17.50 10-Q · filed 2020-05-15 | $0.25 10-Q · filed 2019-05-21 | ||||||
| 2018-12-31 | $111.88 10-K · filed 2020-04-03 | $1.60 10-K · filed 2019-04-10 | ||||||
| 2018-09-30 | $128.80 10-Q · filed 2019-11-14 | $1.84 10-Q · filed 2018-11-19 | ||||||
| 2018-06-30 | $119.00 10-Q · filed 2019-08-14 | $1.70 10-Q · filed 2018-08-13 | ||||||
| 2018-03-31 | $2.55 10-Q · filed 2019-05-21 | $0.17 10-Q · filed 2018-05-15 | ||||||
| 2017-12-31 | $1.95 10-K · filed 2019-04-10 | $0.13 10-K · filed 2018-04-09 | ||||||
| 2017-09-30 | $0.44 10-Q · filed 2018-11-19 | |||||||
| 2017-06-30 | $7.50 10-Q · filed 2018-08-13 | $0.50 10-Q · filed 2017-08-09 | ||||||
| 2017-03-31 | $0.46 10-Q · filed 2018-05-15 | |||||||
| 2016-12-31 | $0.86 10-K · filed 2018-04-09 | |||||||
| 2016-09-30 | $0.89 10-Q · filed 2017-11-20 | |||||||
| 2016-06-30 | $1.04 10-Q · filed 2017-08-09 | |||||||
| 2016-03-31 | $0.00 10-Q/A · filed 2017-06-23 | |||||||
| 2015-12-31 | $2.90 10-K · filed 2017-02-15 | |||||||
| 2015-09-30 | $3.52 10-Q · filed 2016-11-14 | |||||||
| 2014-12-31 | $1.55 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |